{
  "drug_classes": [
    {
      "id": "glp1_ra",
      "ko": "GLP-1 수용체 작용제",
      "en": "GLP-1 receptor agonist",
      "examples": ["semaglutide (Wegovy/Ozempic)", "liraglutide (Saxenda/Victoza)"],
      "korean_status": "급여(당뇨)/비급여(비만), MFDS 승인",
      "typical_weight_loss_pct": "10-15%",
      "rebound_risk": "중등도-고위험"
    },
    {
      "id": "glp1_gip_dual",
      "ko": "GLP-1/GIP 이중작용제",
      "en": "GLP-1/GIP dual agonist",
      "examples": ["tirzepatide (Mounjaro/Zepbound)"],
      "korean_status": "MFDS 승인 (당뇨), 비만 적응증 검토 중",
      "typical_weight_loss_pct": "15-22%",
      "rebound_risk": "중등도"
    },
    {
      "id": "triple_agonist",
      "ko": "GLP-1/GIP/Glucagon 삼중작용제",
      "en": "Triple agonist",
      "examples": ["retatrutide", "survodutide (GLP-1/GCG)"],
      "korean_status": "임상 3상 (KR 참여 일부)",
      "typical_weight_loss_pct": "20-24%",
      "rebound_risk": "데이터 부족"
    },
    {
      "id": "oral_glp1",
      "ko": "경구 GLP-1RA",
      "en": "Oral GLP-1RA",
      "examples": ["oral semaglutide (Rybelsus)", "orforglipron"],
      "korean_status": "Rybelsus MFDS 승인 (당뇨), 비만 적응증 검토",
      "typical_weight_loss_pct": "8-15%",
      "rebound_risk": "중등도"
    },
    {
      "id": "maritide",
      "ko": "MariTide (GIPR antagonist + GLP-1)",
      "en": "MariTide (Amgen)",
      "examples": ["maritide (AMG 133)"],
      "korean_status": "임상 2상",
      "typical_weight_loss_pct": "15-20%",
      "rebound_risk": "유지효과 우수 (durable) 후보"
    },
    {
      "id": "cagrisema",
      "ko": "CagriSema (cagrilintide + semaglutide)",
      "en": "CagriSema",
      "examples": ["cagrilintide+semaglutide"],
      "korean_status": "임상 3상 (REDEFINE)",
      "typical_weight_loss_pct": "15-22%",
      "rebound_risk": "중등도"
    },
    {
      "id": "survodutide",
      "ko": "Survodutide (GLP-1/GCG)",
      "en": "Survodutide",
      "examples": ["survodutide (BI 456906)"],
      "korean_status": "임상 3상",
      "typical_weight_loss_pct": "15-19%",
      "rebound_risk": "데이터 부족"
    },
    {
      "id": "setmelanotide",
      "ko": "Setmelanotide (MC4R agonist)",
      "en": "Setmelanotide",
      "examples": ["setmelanotide (Imcivree)"],
      "korean_status": "MFDS 미승인, 단일유전성 비만 한정",
      "typical_weight_loss_pct": "12-25% (subpheno-specific)",
      "rebound_risk": "낮음 (지속적 복용 시)"
    },
    {
      "id": "metformin",
      "ko": "Metformin",
      "en": "Metformin",
      "examples": ["metformin XR/IR"],
      "korean_status": "급여 (당뇨), 비만 off-label",
      "typical_weight_loss_pct": "2-5%",
      "rebound_risk": "낮음"
    },
    {
      "id": "sglt2i",
      "ko": "SGLT2 억제제",
      "en": "SGLT2 inhibitor",
      "examples": ["empagliflozin", "dapagliflozin"],
      "korean_status": "급여 (당뇨/심부전/CKD)",
      "typical_weight_loss_pct": "2-3%",
      "rebound_risk": "낮음"
    },
    {
      "id": "saxenda",
      "ko": "Liraglutide (Saxenda) 비만용",
      "en": "Liraglutide for obesity",
      "examples": ["liraglutide 3.0mg"],
      "korean_status": "MFDS 승인 (비급여), 12세+ 라벨",
      "typical_weight_loss_pct": "5-8%",
      "rebound_risk": "고위험"
    },
    {
      "id": "orlistat",
      "ko": "Orlistat",
      "en": "Orlistat",
      "examples": ["orlistat 120mg"],
      "korean_status": "MFDS 승인",
      "typical_weight_loss_pct": "3-5%",
      "rebound_risk": "고위험"
    }
  ]
}